Till Holsten

440 total citations
10 papers, 161 citations indexed

About

Till Holsten is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Till Holsten has authored 10 papers receiving a total of 161 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 3 papers in Pathology and Forensic Medicine and 2 papers in Genetics. Recurrent topics in Till Holsten's work include Chromatin Remodeling and Cancer (7 papers), Hedgehog Signaling Pathway Studies (4 papers) and Cancer Mechanisms and Therapy (3 papers). Till Holsten is often cited by papers focused on Chromatin Remodeling and Cancer (7 papers), Hedgehog Signaling Pathway Studies (4 papers) and Cancer Mechanisms and Therapy (3 papers). Till Holsten collaborates with scholars based in Germany, Switzerland and Argentina. Till Holsten's co-authors include Michael C. Frühwald, Kornelius Kerl, Ulrich Schüller, Marcel Kool, Natalia Moreno, Michael Meisterernst, Pascal D. Johann, Sabine Schleicher, Karolina Nemes and Martin Hasselblatt and has published in prestigious journals such as International Journal of Cancer, Cancer Letters and Journal of Neuropathology & Experimental Neurology.

In The Last Decade

Till Holsten

10 papers receiving 158 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Till Holsten Germany 7 124 54 25 24 22 10 161
Tim Heffernan United States 5 101 0.8× 44 0.8× 19 0.8× 8 0.3× 41 1.9× 6 202
Yusuke Isshiki Japan 9 98 0.8× 22 0.4× 29 1.2× 15 0.6× 23 1.0× 20 162
Ben Ho Canada 4 169 1.4× 98 1.8× 47 1.9× 34 1.4× 10 0.5× 10 193
Dias Kurmashev United States 7 116 0.9× 27 0.5× 10 0.4× 21 0.9× 52 2.4× 10 162
Mette Jorgensen United Kingdom 5 45 0.4× 29 0.5× 8 0.3× 20 0.8× 29 1.3× 7 100
Hiromitsu Yamakawa Japan 6 124 1.0× 57 1.1× 20 0.8× 5 0.2× 50 2.3× 9 189
Elisa Cupelli Italy 7 30 0.2× 69 1.3× 14 0.6× 14 0.6× 53 2.4× 9 140
Idoya Zazpe Spain 9 81 0.7× 21 0.4× 56 2.2× 50 2.1× 15 0.7× 18 161
Agnieszka Budziłowska Poland 4 107 0.9× 78 1.4× 11 0.4× 4 0.2× 23 1.0× 6 132
Jennifer A. Arzt United States 4 64 0.5× 58 1.1× 65 2.6× 9 0.4× 52 2.4× 5 151

Countries citing papers authored by Till Holsten

Since Specialization
Citations

This map shows the geographic impact of Till Holsten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Till Holsten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Till Holsten more than expected).

Fields of papers citing papers by Till Holsten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Till Holsten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Till Holsten. The network helps show where Till Holsten may publish in the future.

Co-authorship network of co-authors of Till Holsten

This figure shows the co-authorship network connecting the top 25 collaborators of Till Holsten. A scholar is included among the top collaborators of Till Holsten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Till Holsten. Till Holsten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Niesen, Judith, Jan Sedlacik, Lasse Dührsen, et al.. (2020). Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model. Cancer Letters. 477. 10–18. 10 indexed citations
2.
Holsten, Till, Daniela Börnigen, Stephan Frank, et al.. (2020). Ependymoma relapse goes along with a relatively stable epigenome, but a severely altered tumor morphology. Brain Pathology. 31(1). 33–44. 6 indexed citations
3.
Holsten, Till, Fabiana Lubieniecki, Michael Spohn, et al.. (2020). Detailed Clinical and Histopathological Description of 8 Cases of Molecularly Defined CNS Neuroblastomas. Journal of Neuropathology & Experimental Neurology. 80(1). 52–59. 15 indexed citations
4.
Holsten, Till, Susanne Bens, Florian Oyen, et al.. (2018). Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis. European Journal of Human Genetics. 26(8). 1083–1093. 26 indexed citations
5.
Holsten, Till, Konstantinos Tsiakas, Uwe Kordes, et al.. (2017). Group 3 medulloblastoma in a patient with a GYS2 germline mutation and glycogen storage disease 0a. Child s Nervous System. 34(3). 581–584. 1 indexed citations
6.
Moreno, Natalia, Till Holsten, Pascal D. Johann, et al.. (2017). Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors. Oncotarget. 8(49). 84986–84995. 32 indexed citations
7.
Holsten, Till, Tobias Schuster, Enke Grabhorn, Barbara Hero, & Michael C. Frühwald. (2017). Liver transplantation as a potentially lifesaving measure in neuroblastoma stage 4S. Pediatric Hematology and Oncology. 34(1). 17–23. 6 indexed citations
8.
Kerl, Kornelius, Natalia Moreno, Till Holsten, et al.. (2014). Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. International Journal of Cancer. 135(4). 989–995. 37 indexed citations
9.
Kerl, Kornelius, et al.. (2014). Arsenic Trioxide Inhibits Tumor Cell Growth in Malignant Rhabdoid Tumor Cell In Vitro and In Vivo by Targeting Overexpressed Gli1. Cancer Genetics. 207(9). 452–452. 1 indexed citations
10.
Kerl, Kornelius, Till Holsten, & Michael C. Frühwald. (2013). Rhabdoid Tumors: Clinical Approaches and Molecular Targets for Innovative Therapy. Pediatric Hematology and Oncology. 30(7). 587–604. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tim Heffernan Breakdown of academic impact, for papers by Yusuke Isshiki Breakdown of academic impact, for papers by Ben Ho Breakdown of academic impact, for papers by Dias Kurmashev Breakdown of academic impact, for papers by Mette Jorgensen Breakdown of academic impact, for papers by Hiromitsu Yamakawa Breakdown of academic impact, for papers by Elisa Cupelli Breakdown of academic impact, for papers by Idoya Zazpe Breakdown of academic impact, for papers by Agnieszka Budziłowska Breakdown of academic impact, for papers by Jennifer A. Arzt
Rankless by CCL
2026